Press Releases

SAN FRANCISCO --(BUSINESS WIRE)--Nov. 15, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that Frank Karbe , Chief Executive

U.S. FDA accepted the company’s submission of its de novo request for BT-001 investigational prescription digital therapy for type 2 diabetes in adults BT-001 pivotal clinical trial 90-day results published in peer-reviewed journal Diabetes Care Appointed highly experienced healthcare executive as

SAN FRANCISCO --(BUSINESS WIRE)--Nov. 7, 2022-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced it will release its

Industry Veteran Joins Health Technology Pioneer to Bring Prescription Digital Therapeutics for Type 2 Diabetes and other Cardiometabolic Conditions to Market SAN FRANCISCO --(BUSINESS WIRE)--Oct. 27, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company

ADA -published, peer-reviewed journal article highlights positive primary endpoint data from trial evaluating digitally delivered approach to diabetes management SAN FRANCISCO --(BUSINESS WIRE)--Oct. 4, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT)

Submission follows completion of first-in-class trial demonstrating significant improvements in A1c reduction with investigational therapy targeting the root causes of type 2 diabetes. SAN FRANCISCO --(BUSINESS WIRE)--Sep. 22, 2022-- Better Therapeutics, Inc .

SAN FRANCISCO --(BUSINESS WIRE)--Sep. 7, 2022-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe , Chief

Completed pivotal trial of BT-001 for type 2 diabetes and reported positive secondary endpoint results after 180 days of treatment On track to submit de novo classification request for BT-001 with FDA in third quarter of 2022 Completed enrollment in LivVita Liver Study for nonalcoholic fatty liver

SAN FRANCISCO --(BUSINESS WIRE)--Aug. 4, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will release its second

Data demonstrates BT-001 was durable with A1c reductions continuing to improve after 180 days of treatment On track to submit a de novo classification request with FDA for BT-001 in third quarter of 2022 Company to host conference call and webcast today at 8:30 a.m.